# Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

> **NCT01684098** · PHASE2 · COMPLETED · sponsor: **Endocyte** · enrollment: 40 (—)

## Conditions studied

- Recurrent or Metastatic Cancer
- Head and Neck Cancer
- Pancreas Cancer
- Bladder Cancer
- Testicular Cancer

## Interventions

- **DRUG:** Tc 99m EC20

## Key facts

- **NCT ID:** NCT01684098
- **Lead sponsor:** Endocyte
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 40 (—)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01684098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01684098, "Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01684098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*